---
title: "CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)"
description: "CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274092955.md"
published_at: "2026-01-29T05:07:00.000Z"
---

# CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)

> CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39.6% and a success rate of 59.73%. The consensus for 3SBio is a Strong Buy, with a price target consensus of HK$39.95, indicating a potential upside of 64.66%.

CMB International Securities analyst Jill Wu maintained a Buy rating on 3SBio yesterday and set a price target of HK$37.43. The company’s shares closed yesterday at HK$24.26.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Wu covers the Healthcare sector, focusing on stocks such as BeOne Medicines, CSPC Pharmaceutical Group, and 3SBio. According to TipRanks, Wu has an average return of 39.6% and a 59.73% success rate on recommended stocks.

3SBio has an analyst consensus of Strong Buy, with a price target consensus of HK$39.95, a 64.66% upside from current levels. In a report released on January 27, TipRanks – xAI also reiterated a Buy rating on the stock with a HK$26.00 price target.

### Related Stocks

- [159102.CN - Huaan Hang Seng Biotech ETF](https://longbridge.com/en/quote/159102.CN.md)
- [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 3SBio To Place 105.2 Million Shares | 3SBio Inc :TO PLACE 105.2 MILLION SHARES AT HK$29.62 PER PLACING SHARE | [Link](https://longbridge.com/en/news/268160787.md) |
| 3SBio Proposes Spinoff, Hong Kong Listing of Unit Mandi | 3SBio Proposes Spinoff, Hong Kong Listing of Unit Mandi | [Link](https://longbridge.com/en/news/266844070.md) |
| Kingdom Holding Announces Update On Its Investment In Xai | Kingdom Holding Company announced an update on its investment in Xai following the recent merger with SpaceX. The merger | [Link](https://longbridge.com/en/news/276032953.md) |
| 3SBio Seeks HK$3.12 Billion via Share Sale | 3SBio Seeks HK$3.12 Billion via Share Sale | [Link](https://longbridge.com/en/news/268172267.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.